PACS files 8-K — Item 2.02 Results of Operations

PACS Group, Inc. filed an SEC Form 8-K disclosing Item 2.02 (Results of Operations and Financial Performance) on May 11, 2026, at 16:18:54 ET.

What Was Filed

This EDGAR-submitted 8-K (accessible via https://www.sec.gov/Archives/edgar/data/2001184/000200118426000024/pacsgroupincearningsreleas.htm) delivers the company’s official Q1 2026 earnings release, per SEC guidelines for Item 2.02, which allows public companies to share non-periodic financial performance updates ahead of full quarterly report filings. The filing was accepted alongside a concurrently submitted Q1 2026 10-Q, and aligned with the pre-announced May 11, 2026, release date shared in a May 5, 2026, Business Wire notice.

The Disclosure

For a $5.3B market cap post-acute healthcare financial conglomerate, this Item 2.02 filing includes high-level top-line and bottom-line results: total Q1 2026 revenue of $1.420B, which beat consensus estimates of $1.364B, and no reported actual EPS against a consensus estimate of $0.42. The filing does not include segment-level performance data, full balance sheet metrics, or forward-looking guidance, which will likely be covered during the scheduled May 12, 2026, earnings call.

Cross-Reference to Prior Signals

This earnings release follows two recent insider transaction cycles: March 26, 2026, equity award grants to five executives and co-founder Mark Hancock, including 146,498 shares to President/COO Joshua Jergensen, and April 17, 2026, in-kind share transfers of 288,687 total shares across three officers (CAO Michelle Renee Lewis, CLO John Todd Mitchell, and Jergensen) at a per-share price of $33.14. The current share price of $31.90 is 3.7% below the April 17 grant price. Additionally, analyst ratings have remained static since May 1, 2026, with 2 Strong Buy and 4 Buy ratings, with no changes in the prior 30 days. As of December 31, 2025, institutional ownership of PACS float stood at 28.8%, up 24 quarter-over-quarter to 197 total holders, with total institutional AUM of $1.7B per 13F filings.

What This Filing Does NOT Tell Us

1. Segment-specific revenue breakdowns for senior care, assisted living, and independent living divisions, critical for assessing core operational strength.

2. Full quarterly financial metrics including cash flow, adjusted EBITDA, and balance sheet details, which require reviewing the concurrently filed Q1 2026 10-Q.

3. Forward-looking operational or financial guidance, typically shared exclusively during the May 12, 2026, earnings call rather than this standalone Item 2.02 filing.

4. Compensation terms for newly appointed CFO Carey Hendrickson, announced April 27, 2026, which were not included in this earnings-focused 8-K.